Allergan, Inc Patent Portfolio Statistics

Allergan, Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Allergan, Inc. look like?

Assignee Art Units
Total Applications: 2,781 1,912,264
Granted Patents: 1,758 1,012,365
Grant Index 66.95% 66.82%
Abandoned/Rejected Applications: 868 (33.05%) 502,634 (33.18%)
In-Process Applications: 152 397,265
Average Grant Time: 2.73 Years 2.81 Years
Average Office Actions: 1.77 1.74

Which Technology Area Allergan, Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1626 Organic Chemistry 218
1645 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 166
1627 Organic Chemistry 115
1625 Organic Chemistry 113
1617 Organic Compounds: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs 109

How many patents are Allergan, Inc. filing every year?

Year Total Applications Predicted
2022 0* 578
2021 23* 509
2020 13 388
2019 43 43
2018 53
2017 77
2016 95
2015 131
2014 213
2013 256

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Allergan, Inc. in USPTO?

Publication number: US20170095466A1
Application number: 15/353,262

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.

Publication date: 2017-04-06
Applicant: Allergan, Inc.
Inventors: Dibas I Mohammed

Publication number: US20160310416A1
Application number: 15/048,607

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.

Publication date: 2016-10-27
Applicant: Allergan, Inc.
Inventors: Bakhit Peter

Publication number: None
Application number: 61/709,854


Publication date:
Applicant: Allergan, Inc.
Inventors: Li Ling

How are Allergan, Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
15/353,262 Pharmaceutical Compositions Comprising 7-(1H-Imidazol-4-Ylmethyl)-5,6,7,8-Tetrahydro-Quinoline For Treating Skin Diseases And Conditions Abandoned — Failure to Respond to an Office Action 1627 Karol, Jody Lynn
15/048,607 Compositions Containing Alpha-2-Adrenergic Agonist Components Patented Case 1612 Packard, Benjamin J
61/709,854 Bicyclic 1, 2, 4-Oxadiazoles Derivatives As Sphingosine-1 Phosphate Receptors Modulators Provisional Application Expired